Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

CW Petroleum Corp (OTCQB: CWPE) (the 'Company” or 'CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor ...

The U.S. Food and Drug Administration has already awarded zorevunersen (also known as STK-001) with breakthrough therapy designation for treating Dravet syndrome. Jefferies highlighted that investors ...

According to Jefferies, Phase I/II open-label data suggests zorevunersen can reduce seizures by month six of treatment and improve cognitive and behavioral measures by month nine, indicating ...